Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02640508 2024-05-09

Eribulin and Lenvatinib in Advanced Solid Tumors

Phase 2 Completed

29 enrolled 13 charts

Tumor-Agnostic

Neoplasms

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

1,550 enrolled

Tumor-Agnostic

Neoplasms

NCT05767684 2023-08-25

Neoantigen Derived DCs as Cancer Treatment

Phase 1 Unknown

12 enrolled

Tumor-Agnostic

Neoplasms

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Phase 1/2 Completed

357 enrolled 28 charts 1 FDA

Tumor-Agnostic

Neoplasms

NCT02432274 2023-07-11

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Phase 1/2 Completed

117 enrolled 32 charts

Sarcoma

Neoplasms, Osteosarcoma

NCT00121719 2023-06-22

An Open Label Dose Escalation Study Of E7080

Phase 1 Completed

82 enrolled 34 charts

Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms

NCT01268293 2023-06-22

A Study of E7080 in Subjects With Solid Tumor

Phase 1 Completed

9 enrolled 6 charts

Tumor-Agnostic

Neoplasms

NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Phase 2 Recruiting

24 enrolled

GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms

NCT05322187 2022-04-11

sPLENTY-pc

Phase 2/3 Unknown

15 enrolled

Gastrointestinal

Liver Neoplasms, Neoplasms, Hepatoblastoma

NCT01761266 2022-04-05

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Phase 3 Completed

954 enrolled 19 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT02686164 2019-08-28

Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors

Phase 1 Completed

51 enrolled 11 charts

Tumor-Agnostic

Neoplasms

NCT02846766 2018-08-02

Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling

Phase 2 Withdrawn

Acrocephalosyndactylia, Neoplasms

NCT00280397 2016-10-07

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

Phase 1 Completed

27 enrolled 8 charts

Tumor-Agnostic

Neoplasms

NCT00121680 2015-12-11

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

Phase 1 Completed

115 enrolled

Dermatologic

Melanoma, Neoplasms

NCT00832819 2015-04-30

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

28 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT01240408 2015-03-04

E7080 Food Effect Study in Healthy Subjects

Phase 1 Completed

16 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

MK-4830-001

LIVIGNO-1

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

MK-4280-001

MK-6482-016

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Eribulin and Lenvatinib in Advanced Solid Tumors

DRUP

Neoantigen Derived DCs as Cancer Treatment

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

An Open Label Dose Escalation Study Of E7080

A Study of E7080 in Subjects With Solid Tumor

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

sPLENTY-pc

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors

Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

E7080 Food Effect Study in Healthy Subjects